Lozenge-Formulation and evaluation of Ebastine and Phenylephrine lozenges

Nisarg Bhatt

Lozenge-Formulation and evaluation of Ebastine and Phenylephrine lozenges

Nisarg Bhatt

Saraswati Institute of Pharmaceutical Sciences, India

: J Pharm Drug Deliv

Abstract

Ebastine (EBA) and Phenylephrine HCl (PHE) were formulated as lozenges to provide effective release for treatment of Upper Respiratory Tract Infection (URTI). Many dosage forms like syrups, tablets, capsules are available in the market but still there is a need for new dosage forms which acts effectively and locally. Present investigation was undertaken to formulate and evaluate lozenges to meet the need of improved in patient conveniences. Ebastine have poor solubility. Here different inclusion complexes with various concentrations of ÃŽÂ²-CD were formed by different method for enhancement in solubility of Ebastine. Two types of lozenges were prepared, Hard candy lozenges and Compressed tablet Lozenges. Hard candy lozenges were prepared by heating and congealing method, and compressed tablet lozenges prepared by wet granulation method. Prepared lozenges were subjected to various evaluation parameters. After completion of stability study for a period of one month, the optimized formulations were subjected to evaluations parameters. Hard candy lozenges formulated using Mannitol and 0.5 ml Glycerine (F10) was found optimized. In compressed tablet lozenges, with concentration of 5% Gelatin (T2) it found optimized. So, here F10 and T2 were optimized lozenge formulation. From the present work it was concluded that Kneading method shows satisfactory enhancement in Ebastine solubility. Considering all above mentioned facts it can be concluded that hard candy and compressed tablet lozenges of EBA and PHE shows desirable features such as Hardness, Disintegration time and Drug release behavior. The lozenges can provide an attractive alternative formulation in the treatment of URTI.